Rohith Haliyur Shivanna | Microbiology | Best Researcher Award

Dr. Rohith Haliyur Shivanna | Microbiology | Best Researcher Award

Icahn School of Medicine at Mount Sinai | United States

Dr. Rohith H. Shivanna is a dedicated biotechnologist and microbiologist with over nine years of research experience and one year of industry exposure. Currently serving as a Post-Doctoral Fellow in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, New York, USA, Dr. Shivanna has extensive expertise in molecular microbiology, food product development, and probiotics.

Professional profileπŸ‘€

Google Scholar

Strengths for the Awards✨

  • Extensive Research Experience: Nine years of diverse research across molecular microbiology, fermentation technology, probiotics, and genetics.
  • Interdisciplinary Expertise: Combines knowledge in microbiology, biotechnology, food product development, genetics, and genomic sciences.
  • Practical Skills: Mastery in molecular biology, fermentation, product development, and advanced techniques like ATAC-sequencing and chromatin remodeling.
  • Publication and Conference Contributions: Presented at multiple prestigious conferences, highlighting his active engagement with the scientific community.
  • Leadership and Collaboration: Worked under esteemed mentors and contributed to numerous projects, showcasing collaboration and leadership abilities.
  • Global Research Exposure: Current post-doctoral role at the Icahn School of Medicine at Mount Sinai, New York, demonstrates global recognition and engagement.

πŸŽ“ Education

  • Ph.D. in Biotechnology (2017-2022, awarded in 2023) – CSIR-CFTRI, Mysuru, Mangalore University, India.
  • M.Sc. in Biotechnology (2010-2012) – University of Mysore, India (7.3 CGPA).
  • B.Sc. in Biochemistry, Microbiology, and Biotechnology (2007-2010) – University of Mysore, India (63.10%).

πŸ’Ό Experience

  • Post-Doctoral Fellow (May 2023 – Present) – Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Project/Technical Assistant (June 2022 – May 2023) – NPIC-CIF Dept., CSIR-CFTRI, Mysore, India.
  • Ph.D. Researcher (May 2017 – June 2022) – Microbiology and Fermentation Department, CSIR-CFTRI, Mysore, India.
  • Project Assistant (May 2015 – March 2017) – CSIR-CFTRI, Mysore, India.
  • Clinical Process Associate-2 (October 2014 – April 2015) – Quintiles Research Pvt. Ltd., Bangalore, India.
  • Project Assistant (August 2013 – September 2014) – Food Microbiology Department, CSIR-CFTRI, Mysore, India.
  • R&D Trainee (February 2013 – July 2013) – Bacardi India Pvt. Ltd., Nanjangud, Mysore, India.

πŸ”¬ Research Interests On Microbiology

Dr. Shivanna’s research focuses on probiotics, microbiology, fermentation technology, immune modulation, food product development, genetic studies, chromatin remodeling, and molecular mechanisms of inflammatory diseases.

πŸ† Awards

  • ICMR-SRF Fellowship – Awarded during Ph.D. research.
  • Recognition for Poster Presentation at multiple conferences, including the Probiotics Association of India and International Symposium on Probiotics & Immunity.

πŸ“š Publications

  • Title: The Combined Effect of Potential Probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 Towards Anti-inflammatory Activity on HT-29
    Authors: R. H. S., P. M. Halami
    Year: 2021
    Citations: 24

  • Title: In vitro validation studies for adhesion factor and adhesion efficiency of probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 on HT-29
    Authors: H. S. Rohith, P. M. Halami
    Year: 2021
    Citations: 22

  • Title: Probiotic Bacillus licheniformis MCC2514 and Bifidobacterium breve NCIM 5671 Regulates GATA3 and Foxp3 Expression in the Elevated Disease Condition
    Authors: H. S. Rohith, M. S. Peddha, P. M. Halami
    Year: 2024
    Citations: 5

  • Title: Efficacy of probiotic bacteria in alleviating T helper cell-associated immune response
    Authors: H. S. Rohith
    Year: 2022

  • Title: In Vitro Validation Studies For Adhesion Factor and Adhesion Efficiency of Probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 on HT-29 Cell Lines
    Authors: R. H. S., P. M. Halami
    Year: 2021

  • Title: Aqueous two phase system for downstream processing of proteins
    Authors: A. S. Bhandiwad, B. S. Karanth, H. S. Rohith, T. B. S. Gowda
    Year: 2002

πŸ” Conclusion

Dr. Rohith H. Shivanna’s journey in biotechnology and microbiology reflects a strong commitment to advancing scientific knowledge and developing practical applications for health and nutrition. His diverse research interests, practical skills, and international experience position him as a rising expert in the field, contributing significantly to both academia and industry.

Guoying Ni | Microbiology | Best Researcher Award

Prof. Dr. Guoying Ni | Microbiology | Best Researcher Award

CEO | Zhongao Biomedical Technology (Guangdong) Co., Ltd | Australia

Dr. Guoying Ni is an esteemed researcher specializing in the tumor microenvironment and immunotherapy. With a PhD from Griffith University School of Medicine, Australia, Dr. Ni has dedicated nearly 15 years to groundbreaking research at the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Dr. Ni’s research has led to significant advancements, including the application of nanostructured graphene oxide for targeted immunotherapy and the discovery of tumor-inhibiting properties of Caerin peptides from Australian tree frogs.

Profile

Scopus

Strengths for the Awards

  • Extensive Research Experience – Dr. Ni has been engaged in tumor microenvironment and immunotherapy research for nearly 15 years across multiple institutions in Australia and China.
  • Innovative Contributions – Key contributions include using nanostructured graphene oxide for IL-10R antibody delivery and discovering the tumor-inhibitory effects of Caerin peptides.
  • High-Impact Publications – With nearly 60 research papers published in prestigious journals (Q1-ranked, impact factor over 12), Dr. Ni’s work demonstrates strong academic influence.
  • Funding and Grants – Dr. Ni has secured over 20 million RMB in research funding, showing recognition and support from funding bodies.

Education πŸŽ“

Dr. Ni obtained a PhD from Griffith University School of Medicine, Australia. During this time, extensive research in immunotherapy and molecular biology laid the foundation for Dr. Ni’s expertise in cancer treatment methodologies.

Experience 🌟

Dr. Ni has held pivotal research positions at multiple prestigious institutions, including the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Key contributions include developing a novel antibody delivery system using graphene oxide nanoparticles and evaluating anti-IL-10R antibody peptides in vitro and in vivo. Additionally, Dr. Ni has over eight years of experience supervising master’s and PhD students across Australia and China.

Research Interest On Microbiology πŸ“š

Dr. Ni’s research focuses on tumor immunotherapy, nanomedicine, and molecular oncology. Notable areas of interest include:

  • Graphene oxide as a targeted antibody delivery system
  • Anti-IL-10R therapy in cancer treatment
  • Caerin peptides for tumor suppression and immune response activation
  • Peptide-based immunotherapies for clinical applications

Awards & Honors πŸ†

  • 2022-2023: DVCR/A Launch Research Grant/Award, University of the Sunshine Coast, Australia
  • 2016-2017: HDR Merit Research Grant, Griffith University, Australia
  • 2013: GRPRS Scholarship and HDR Scholarship, Griffith University
  • Visiting Professor: Guangdong Pharmaceutical University, First People’s Hospital of Foshan, Guangdong Province

Publications πŸ“„

  1. Title: Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages
    • Authors: Fu, Q.; Luo, Y.; Li, J.; … Ni, G.; Wang, T.
    • Publication Year: 2024
    • Citations: 0
  2. Title: Caerin 1.9–Titanium Plates Aid Implant Healing and Inhibit Bacterial Growth in New Zealand Rabbit Mandibles
    • Authors: Long, Y.; Duan, X.; Fu, Q.; … Liu, X.; Yang, W.
    • Publication Year: 2024
    • Citations: 0
  3. Title: Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1
    • Authors: Wang, Y.; Zhong, F.; Xiao, F.; … Wang, T.; Zhang, W.
    • Publication Year: 2024
    • Citations: 1
  4. Title: Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
    • Authors: Fu, Q.; Luo, Y.; Li, J.; … Wang, T.; Ni, G.
    • Publication Year: 2024
    • Citations: 0
  5. Title: Proteomic analysis of anti-MRSA activity of caerin 1.1/1.9 in a murine skin infection model and their in vitro anti-biofilm effects against Acinetobacter baumannii
    • Authors: Zhang, P.; Tang, S.; Fu, Q.; … Chen, G.; Liu, X.
    • Publication Year: 2023
    • Citations: 2
  6. Title: Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer
    • Authors: Liu, X.; Ni, G.; Zhang, P.; … Yuan, S.; Wang, T.
    • Publication Year: 2023
    • Citations: 10
  7. Title: Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria
    • Authors: Cavallazzi Sebold, B.; Li, J.; Ni, G.; … Liu, X.; Wang, T.
    • Publication Year: 2023
    • Citations: 6
  8. Title: Experimental study of 131I-caerin 1.1 and 131I-c(RGD)2 for internal radiation therapy of esophageal cancer xenografts
    • Authors: He, T.; Du, J.; Zhu, K.; … Zhang, P.; Yuan, J.
    • Publication Year: 2023
    • Citations: 2
  9. Title: Degradation of differently processed Mg-based implants leads to distinct foreign body reactions (FBRs) through dissimilar signaling pathways
    • Authors: Liu, X.; Chen, G.; Zhong, X.; … Gao, M.; Li, H.
    • Publication Year: 2023
    • Citations: 5
  10. Title: PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
  • Authors: Cavallazzi Sebold, B.; Ni, G.; Li, J.; … Liu, X.; Wang, T.
  • Publication Year: 2023
  • Citations: 3

Conclusion πŸŽ‰

Dr. Guoying Ni is a trailblazer in tumor immunotherapy and nanomedicine. With numerous research contributions, multiple prestigious awards, and collaborations with globally recognized scientists, Dr. Ni continues to push the boundaries of medical research to develop innovative cancer treatments. Through dedication and expertise, Dr. Ni’s work is making a significant impact on the future of cancer immunotherapy.

Lina Fan | Microbiology | Best Researcher Award

Dr. Lina Fan | Microbiology | Best Researcher Award

Distinguished researcher | The Second Affiliated Hospital of Zhejiang University School of Medicine | China

Lina Fan is a distinguished researcher and physician, specializing in gut microbiota, immune microenvironment, and colorectal tumorigenesis. She obtained her Ph.D. from Zhejiang University and currently works as a gastroenterologist at the Second Affiliated Hospital of Zhejiang University School of Medicine. Her work focuses on the intricate relationship between gut microbiota and cancer, contributing significantly to the field with several impactful publications.

Profile

Scopus

Strengths for the Awards

  • Strong Academic Background:
    • Lina holds a Ph.D. from Zhejiang University, a prestigious institution, and works as a distinguished researcher and physician.
  • Research Focus:
    • Her research is centered on the highly impactful areas of gut microbiota, immune microenvironment, and colorectal cancer, all of which have significant implications for medical science.
  • High-Quality Contributions:
    • She has contributed significantly to the understanding of gut microbiota’s relationship with colorectal cancer and immune microenvironments, evidenced by the completion of substantial research on Bifidobacterium adolescentis and other microbiota in colorectal cancer.
  • Publications and Editorial Appointments:
    • Although there is no explicit mention of indexed journal publications, Lina holds editorial positions in well-regarded journals such as Cancer Immunology Research, Gut Microbes, and Cancer Communications, showcasing recognition from the research community.

Education πŸŽ“

Lina Fan earned her Ph.D. from Zhejiang University, where she honed her expertise in gastrointestinal research. As a researcher and physician, she has contributed to advancements in understanding the immune microenvironment and gut microbiota’s role in colorectal cancer, laying the foundation for her future work.

Experience πŸ₯

Lina has served as a gastroenterologist and researcher at the Second Affiliated Hospital of Zhejiang University School of Medicine. She has been actively involved in studies examining the gut microbiota, immune system, and their relationship to digestive cancers, particularly colorectal cancer, producing multiple high-impact research articles in the process.

Research Interests On MicrobiologyπŸ”¬

Her research interests center on gut microbiota, the immune microenvironment, and their roles in colorectal tumorigenesis. Specifically, Lina has worked on understanding how specific microbes, like Bifidobacterium adolescentis, influence cancer development. Her ongoing projects explore the effects of gut microbiota on metabolic syndrome and the immune response in cancer.

Awards πŸ†

Lina has been nominated for prestigious awards, including the Young Scientist Award and the Best Researcher Award, recognizing her groundbreaking work in cancer immunology and microbiome research. Her research has been recognized both nationally and internationally for its innovation and contributions to the scientific community.

Publications πŸ“°

  • Lactobacillus intestinalis facilitates tumor-derived CCL5 to recruit dendritic cell and suppress colorectal tumorigenesis
    • Authors: Sun, Y., Wang, Q., Jiang, Y., Chen, S., Fan, L.
    • Year: 2025
    • Citations: 0
  • Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer
    • Authors: Jia, D., Wang, Q., Qi, Y., Chen, S., Wang, L.
    • Year: 2024
    • Citations: 47
  • Correction: Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis
    • Authors: Lin, Y., Fan, L., Qi, Y., Chen, S., Wang, L.
    • Year: 2023
    • Citations: 0
  • Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis
    • Authors: Lin, Y., Fan, L., Qi, Y., Chen, S., Wang, L.
    • Year: 2023
    • Citations: 19
  • Bifidobacterium adolescentis orchestrates CD143+ cancer-associated fibroblasts to suppress colorectal tumorigenesis by Wnt signaling-regulated GAS1
    • Authors: Chen, S., Fan, L., Lin, Y., Si, J., Wang, L.
    • Year: 2023
    • Citations: 14
  • Lactobacillus johnsonii alleviates colitis by TLR1/2-STAT3 mediated CD206+ macrophagesIL-10 activation
    • Authors: Jia, D.-J.-C., Wang, Q.-W., Hu, Y.-Y., Chen, S.-J., Wang, L.-J.
    • Year: 2022
    • Citations: 70
  • Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-induced acute colitis by NLRP3 activation
    • Authors: Qu, S., Fan, L., Qi, Y., Liu, W., Si, J.
    • Year: 2021
    • Citations: 153
  • Akkermansia muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs
    • Authors: Fan, L., Xu, C., Ge, Q., Chen, S., Wang, L.
    • Year: 2021
    • Citations: 94
  • Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization
    • Authors: Xu, C., Fan, L., Lin, Y., Si, J., Chen, S.
    • Year: 2021
    • Citations: 146
  • Bifidobacterium adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling
    • Authors: Fan, L., Qi, Y., Qu, S., Si, J., Chen, S.
    • Year: 2021
    • Citations: 141

Conclusion

Dr. Lina Fan’s research has made significant strides in exploring the complex relationship between gut microbiota and colorectal cancer. Her work continues to shape the field, with groundbreaking findings that may lead to novel therapeutic strategies. With her commitment to advancing medical knowledge, she is undoubtedly a key figure in the scientific community.